Unraveling the cardiotoxic effects of wild-type and variant transthyretin: insights from in vitro models

29 August 2025 (07:00 - 18:00)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Miss Angeliki Choustoulaki

National & Kapodistrian University of Athens, Athens (Greece)

9 More presentations in this session

Presentation thumbnail

Discussant - Molecular mechanisms and genetic insights in cardiomyopathies

Presentation thumbnail

Discovery and verification of disulfidptosis-associated gene expression alterations in hypertrophic cardiomyopathy

Doctor X. Tan (Suzhou, CN)

Abstract Slides Video

Presentation thumbnail

Whole-exome sequencing generated polygenic risk score and risk stratification in Taiwanese genetic cardiomyopathies: a nation-wide sudden arrhythmia death syndrome (SADS) Taiwan registry

Doctor H. Tseng (Hsinchu, TW)

Abstract Slides Video

Presentation thumbnail

Alternative RNA splicing in genetic and ischemic dilated cardiomyopathy

Doctor Y. Devaux (Luxembourg, LU)

Abstract Slides Video

Presentation thumbnail

Comprehensive genetic analysis of desmoglein-2 in arrhythmogenic cardiomyopathy

Associate Professor K. Pilichou (Padova, IT)

Access the full session

Session thumbnail

New perspectives in cardiology (4) - Molecular mechanisms and genetic insights in cardiomyopathies

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025

You may be interested in

Congress Presentation

Engineering hiPSC-derived tissue models for advanced amyloidosis research and therapy development

Congress Presentation

Predictors and outcomes of amyloid cardiomyopathy caused by transthyretin V30 mutation

Congress Presentation

Transthyretin stabiliser therapy in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources